CPI-613 on FDA Fast Track to Treat AML

CPI-613 on FDA Fast Track to Treat AML

281894

CPI-613 on FDA Fast Track to Treat AML

CPI-613 (devimistat) has been granted a fast track designation by the U.S. Food and Drug Administration to treat acute myeloid leukemia (AML), announced its developer, Rafael Pharmaceuticals. The designation is intended to accelerate a candidate therapy’s development and expedite its approval. “Receiving Fast Track designation, especially during a pandemic that has created significant challenges for many trials across the globe, is a testament to the dedicated work of the Rafael team,” Sanjeev Luther, company president…

You must be logged in to read/download the full post.